aXichem AB (publ), (aXichem), developer of innovative natural analogue feed additives and dietary supplement ingredients, announces that the company has taken out a credit facility of five million SEK with support from the European Investment Fund (EIF). The credit is being taken out with the aim of securing financing to produce aXichem's feed additive aXiphen, for delivery to the company's distributor in Brazil, Chr. Olesen. As previously announced, Chr. Olesenplaced an order for aXiphen worth approximately seven million SEK in February this year. The order will be delivered by call-off in 2025.
Torsten Helsing, CEO of aXichem, comments:
"It is very positive that through this credit facility and the support from the EIF, we can cost-effectively produce and deliver aXiphen in line with market expectations. With support from the EIF, the company has a flexible financial solution for continued expansion in the animal feed market in Brazil."
The information was submitted, through the care of the contact person below, for publication on 18 March 2025, at 08:30 AM CET.
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
